恩替卡韦治疗失代偿期乙肝肝硬化的疗效观察

摘要

Objective To investigate the effect of entecavir in treatment of patients with decompensated hepatitis B cirrhosis.Methods 82 cases of patients with decompensated liver cirrhosis were treated with conventional therapy (control group 41 cases) and added entecavir treatment (observation group, 41 cases) were observed the treatment effect and the incidence of the statistics adverse reactions.Results The patients in the observation group after treatment TBil, ALT, Alb and other indexes of liver function compared with the control group there were significant differences and were better than the control group (P<0.05). Patients in the observation group after treatment of liver function and the integral control group were compared and there was a significant difference than the control group (P<0.05).Conclusion The addition of grace in the routine diuretic therapy of entecavir in treatment of decompensated liver cirrhosis patients with obvious effect, to improve liver function index of patients, improve the liver function of patients with optimal degree had a good effect.%目的：探讨恩替卡韦治疗失代偿期乙肝后肝硬化患者的效果。方法将82例失代偿期乙肝后肝硬化患者分别给予常规治疗（对照组41例）+恩替卡韦治疗（观察组41例），观察患者治疗效果。结果观察组患者治疗后总胆红素（TBil）、丙氨酸氨基转移酶（ALT）、血清白蛋白（Alb）等肝功能指标与对照组患者相比，均优于对照组，差异有统计学意义（P＜0.05）。观察组患者治疗后肝功能积分与对照组患者相比，优于对照组，差异有统计学意义（P＜0.05）。结论在常规保肝利尿治疗基础上添加恩替卡韦治疗失代偿期乙肝后肝硬化患者效果显著，对改善患者肝功能指标、提高患者肝功能优化程度等均有良好效果。